Clinical Trial Search

Primary: Number of Participants Who Died — 5; 5; 5 Participants

Primary: Freedom From Seizure — 7 individuals

Primary: Mean Maximum Temperature — 38.6; 39.2 degrees of Celsius — p=<0.0001

Primary: Sensitivity and Specificity of ASPIRE to Detect Malarial Retinopathy in Eyes of the Subjects Clinically Diagnosed With CM — 87; 85 Percentage of participants

Primary: Number of Clinical Malaria Episodes Per Year of Follow-up — 0.61; 0.68; 0.64; 0.59 Episodes per PYAR — p=0.8097

Primary: Minutes With Seizure on EEG — 165.2; 464.8 minutes with seizure

Primary: Percentage of Participants Achieving at Least 90% Reduction in Plasmodium Falciparum (P. Falciparum) at 12 Hours — 80.0; 93.0; 39.3 percentage of participants

Primary: Changes in Haemoglobin Concentration From Day 3 Post Treatment of Malaria Episode to Day 90 in the Weekly Chloroquine and Placebo Arms — 93.4; 93.7 g/L

Primary: Change in Haemoglobin Compared to the Baseline — 0.18; 0.54 g/dl

Primary: Participants With Local Adverse Events (AEs) - Year One — 3; 1; 0; 0 Participants

Primary: Parasitological Success (MITT) — 66; 28; 4; 43 participants — p=<0.005

Primary: Number of Participants With Local Adverse Events (AEs) — 0; 1; 1; 1 Participants

Primary: Parasite Clearance Half-life — 1.733; 1.973 Hours — p=>0.05

Primary: Participants With Local Adverse Events (AEs) — 1; 0; 0; 2 Participants

Primary: Incidence and Severity of Observed or Self-reported Adverse Events (AEs) Considered PfSPZ-DVI Challenge Inoculum-related. — 13; 12; 1; 2 Incidence

Primary: Safety and Reactogenicity (SAEs and AEs) — 45; 53; 22; 37 Number of events

Primary: Number of Participants With Positive Sensitive Blood Smear (sBS) — 0; 0 Participants

Primary: Infection Rate — 5; 6; 3; 0 Participants

Primary: Cure Rates of AQ-13 and Coartem for Uncomplicated Plasmodium Falciparum Malaria in Adult Malian Males. — 28; 31 Participants

Primary: Drug-specific Parasite Reduction Ratio (PRR48) of ACT-451840 Over 48 Hours Using a Standardized Approach — 234.5 Ratio

Primary: Subjects Time to First Clinical Episode of P Falciparum Malaria During the Efficacy Follow-up Period Adjusted for Time at Risk - Intent to Treat (ITT) Population — 107…

Primary: Absence of Malaria Parasites in Blood. — 73 Participants

Primary: Cure Rate on Day 28 — 197; 603 Participants — p=>0.05

Primary: Change in Percentage of Parasites Detected at 48 Hours — 99.998 percentage of parasite change

Primary: Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the First Vaccination — 0; 5; 0; 12 Participants

Primary: Percentage of Participants With Parasite Clearance at Day 28 — 97.20 percentage of participants

Primary: Parasitological Success Defined as a Reduction in Parasite Count of ≥ 90% of Baseline at 24 Hours After the First Dose — 14; 10 participants — p=0.17

Primary: Incidence of Clinical Malaria Per Patient Year — 0.04; 3.05; 1.36 episodes/patient year

Primary: Incident Malaria Cases Per Person Year at Risk in HIV-unexposed Participants — 6.95; 6.73; 5.21; 3.02 Episode per person year at risk — p=0.57

Primary: Number of Participants With Solicited or Unsolicited Symptoms Reporting During the Post-vaccination Period — 10; 10; 9; 10 participants